Copyright © 1994 by the European Society of Cardiology.
© 1994 The European Society of Cardiology
Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction
Department of Cardiology Söder Hospital, Stockholm
*Department of Pharmacology, Karolinska Institute Stockholm, Sweden
Received 24 May 1993; revised 26 November 1993; .
Correspondence: Dr Bengt Ullman, Department of Cardiology, Soder Hospital, S-118 83, Stockholm, Sweden
Abstract
Plasma neuropeptide Y-like immunoreactivity (NPY-LI) is elevated in patients with acute myocardial ischaemia and congestive heart failure (CHF) owing to increased activity of the sympathetic nervous system. The prognostic value of plasma NPY-LI with regard to mortality was studied in 324 random patients athnitted to a coronary care unit. The one-year mortality was 37% in 113 patients with acute myocardial infarction (AMI) and 18% in those without AMI. Several factors were tested by multiple logistical regression analysis to predict the one-year mortality Plasma NPY-LI >60 pmol. l–1, advanced age and previous CHF were independent prognostic factors for an increased risk of mortality in patients without AMI. The mortality rate after one year in non-AMI patients with plasma NPY-LI 
60 pmol. l–1 was l4% compared to 69% in those with plasma NPY-LI >60 pmol. l–1. Increased heart rate was the only independent prognostic factor for increased mortality in AMI patients.
Plasma NPY-LI on admission was an independent predictor of mortality in CCU patients without AMI and thus resembles plasma noradrenaline.
Key Words: Neuropeptide Y • noradrenaline • prognosis • mortality • congestive heart failure • myocardial infarction
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Y. Callanan, E. W. Lee, J. U. Tilan, J. Winaver, A. Haramati, S. E. Mulroney, and Z. Zukowska Renal and cardiac neuropeptide Y and NPY receptors in a rat model of congestive heart failure Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1811 - F1817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zoccali, F. Mallamaci, G. Tripepi, F. A. Benedetto, S. Parlongo, S. Cutrupi, D. Iellamo, G. Bonanno, F. Rapisarda, P. Fatuzzo, et al. Prospective Study of Neuropeptide Y as an Adverse Cardiovascular Risk Factor in End-Stage Renal Disease J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2611 - 2617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Karvonen, M. Koulu, U. Pesonen, M. I. J. Uusitupa, A. Tammi, J. Viikari, O. Simell, and T. Rönnemaa Leucine 7 to Proline 7 Polymorphism in the Preproneuropeptide Y Is Associated with Birth Weight and Serum Triglyceride Concentration in Preschool-Aged Children J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1455 - 1460. [Abstract] [Full Text]
|
|